A diversified pipeline built on our AI-powered platforms
of AAV, mRNA, cell therapy and in vivo CAR-T

Diversified and Comprehensive Pipeline

Our company has established an AI-powered comprehensive technical platform of AAV, mRNA, cell therapy, and in vivo CAR-T. Our pipeline covers the therapeutic areas with high unmet medical needs and bright market prospects including neurology, ophthalmology, oncology, vascular diseases, and chronic wounds.

mRNACell therapyin vivo CAR-TAAV
← Swipe to see the full table →
PlatformProductIndicationDiscoveryIITPh IPh IIPh IIINDA
ONCOLOGY
mRNA
RGL-270
Solid tumorPDAC / NSCLC / GC / HCC, etc.
RGL-232
Solid tumorPDAC / NSCLC / CRC
Cell therapy
RGL-305
B-NHL & HCC
Undisclosed
Undisclosed
Undisclosed
Undisclosed
in vivo CAR-T
Undisclosed
Undisclosed
Undisclosed
Undisclosed
NON-ONCOLOGY
mRNA
RGL-2102
Critical limb ischemia
RGL-2102(T)
Chronic wound
RGL-236
Osteoarthritis
AAV
RGL-193
Parkinson’s disease
RGL-2201
Wet AMD
RGL-185
Xerostomia

Last updated: September 2026